Biotech Innovation
AbbVie's aggressive M&A, FDA reverses stance on gene therapy—biopharmaceutical industry enters a new cycle
AbbVie acquires Apogee for nearly $11 billion, Sanofi changes leadership to address patent cliff, FDA reverses stance on gene therapy, and industry signals from BIO 2026 conference.
Introduction
In the second quarter of 2026, the wave of mergers and acquisitions in the biopharmaceutical industry continued to heat up, while uncertainty surrounding regulatory policies once again became a focal point. AbbVie acquired Apogee Therapeutics for approximately $10.9 billion, strengthening its immunology pipeline; meanwhile, the FDA made a dramatic reversal in its stance on gene therapy, removing obstacles for new drug applications from uniQure and REGENXBIO. At the same time, Sanofi replaced its head of R&D to address the patent cliff for Dupixent, and predictions regarding Eli Lilly's weight-loss drug became a hot topic in the industry. These events collectively outline a complex landscape of capital operations, regulatory evolution, and innovation breakthroughs.
Industry Background
After a downturn in 2024, M&A activity has rebounded significantly since 2025. According to BioSpace, the biopharmaceutical sector saw 19 deals in the first quarter of 2026, totaling nearly $47 billion. Facing patent cliffs, large pharmaceutical companies are replenishing their pipelines through acquisitions. Meanwhile, policy volatility under the leadership of acting FDA Commissioner Kyle Diamantas has added to industry uncertainty.
Key Developments
AbbVie Acquires Apogee Therapeutics
In June, AbbVie announced the acquisition of Apogee Therapeutics for approximately $10.9 billion, gaining its lead IL-23 inhibitor—an investigational drug for atopic dermatitis. This deal follows GSK's $10.5 billion acquisition of Nuvalent Bio, making it the second-largest M&A transaction in the first half of the year. The move is aimed at strengthening AbbVie's position in immunology and complementing its blockbuster drugs Skyrizi and Rinvoq.
FDA Reverses Stance on Gene Therapy Approvals
The FDA recently changed its attitude toward gene therapies from uniQure and REGENXBIO. uniQure's gene therapy for Huntington's disease was previously required to provide additional data, but the FDA now considers the existing data sufficient to support submission. REGENXBIO's gene therapy for Hunter syndrome has also been permitted to resubmit its application. Both companies plan to submit or resubmit their new drug applications in the third quarter of 2026. This reversal reflects the FDA's re-evaluation of the risks and benefits in the gene therapy field.
Sanofi R&D Restructuring### Sanofi R&D Restructuring
Sanofi CEO Belén Garijo announced the appointment of Paulo Fontoura, former executive of AI biotech company Xaira, as R&D head, succeeding the departing Houman Ashrafian. This move is part of Sanofi's pipeline reinforcement to address the patent cliff for Dupixent (sales exceeding $10 billion in 2026, expected to expire around 2031).
BIO 2026 Conference Updates
The BioSpace editorial team reported from the BIO 2026 conference in San Diego that industry enthusiasm is high, deal discussions are active, and AI and gene therapies are hot topics.
Eli Lilly's Weight-Loss Drug Prospects
According to an Evaluate report, Eli Lilly’s tirzepatide franchise (including Mounjaro and Zepbound) is projected to become the best-selling drug in history by 2032, with annual sales exceeding $70 billion, accounting for nearly half of the total sales of the top 10 global drugs that year. However, Lilly is not stopping there, also eyeing assets from biotech company Sangamo, which has filed for bankruptcy protection.
Market Impact
Active M&A indicates that large pharmaceutical companies are actively addressing patent cliffs by acquiring early-stage assets to supplement pipelines. AbbVie’s acquisition of Apogee will directly compete with Sanofi’s Dupixent in the atopic dermatitis market. The FDA’s reversal on gene therapy could accelerate the commercialization of this field, providing more treatment options for patients, but also raising concerns about regulatory consistency. Sanofi’s appointment of an executive with an AI background signals an industry trend toward improved R&D efficiency.
Reader cross-check · medtechdaily
medtechdaily frames this note through Digital Health / AI Healthcare / Medical Devices - Source links should be opened before the summary is reused. dates, names and status changes still need checking; Digital Health / AI Healthcare / Medical Devices explains the local editorial angle.